NASDAQ:GNCA - Genocea Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.54 +0.01 (+1.89 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$0.53
Today's Range$0.52 - $0.55
52-Week Range$0.28 - $1.25
Volume264,600 shs
Average Volume254,569 shs
Market Capitalization$46.78 million
P/E Ratio-0.28
Dividend YieldN/A
Beta2.94
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNCA
CUSIPN/A
Phone617-876-8191

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$230,000.00
Book Value($0.21) per share

Profitability

Net Income$-56,710,000.00

Miscellaneous

Employees52
Market Cap$46.78 million
Next Earnings Date2/28/2019 (Confirmed)
OptionableOptionable

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences Inc (NASDAQ:GNCA) released its earnings results on Friday, August, 10th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.08. View Genocea Biosciences' Earnings History.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Genocea Biosciences.

What price target have analysts set for GNCA?

2 analysts have issued 12-month price targets for Genocea Biosciences' stock. Their predictions range from $5.00 to $5.00. On average, they expect Genocea Biosciences' share price to reach $5.00 in the next year. This suggests a possible upside of 825.9% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.

What is the consensus analysts' recommendation for Genocea Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.

What are Wall Street analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:
  • 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (11/8/2018)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $5 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, GEN-009. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (11/1/2018)
  • 3. Cantor Fitzgerald analysts commented, "GNCA shares could experience some weakness on the news of the departure of the CFO, Jonathan Poole, who resigned effective 3/23, to pursue other opportunities." (3/11/2018)

Has Genocea Biosciences been receiving favorable news coverage?

News articles about GNCA stock have trended positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genocea Biosciences earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of Genocea Biosciences' key competitors?

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), Endologix (ELGX), CA (CA), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), BlackRock (BLK), Micron Technology (MU), Gran Tierra Energy (GTE), Black Diamond Group (BDI) and Hudson Technologies (HDSN).

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the folowing people:
  • Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)
  • Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)
  • Dr. Darren Higgins, Scientific Co-Founder & Member of Scientific Advisory Board
  • Mr. Michael Alfieri, Principal Financial Officer & Principal Accounting Officer (Age 54)
  • Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $0.54.

How big of a company is Genocea Biosciences?

Genocea Biosciences has a market capitalization of $46.78 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-56,710,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Genocea Biosciences employs 52 workers across the globe.

What is Genocea Biosciences' official website?

The official website for Genocea Biosciences is http://www.genocea.com.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]


MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel